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Synthesis, in vitro safety and antioxidant activity 
of new pyrrole hydrazones
Six new N-pyrrolylhydrazide hydrazones were synthesized 
under micro synthesis conditions, assuring about 59–93 % 
yield, low harmful emissions and reagent economy. The struc-
tures of the new compounds were elucidated by melting 
points, TLC characteristics, IR, 1H and 13C NMR spectral data 
followed by MS data. The purity of the obtained compounds 
was proven by the corresponding elemental analyses. “Lipin-
ski’s rule of five” parameters were applied for preliminary 
evaluation of the pharmacokinetic properties of the target 
molecules. The initial in vitro safety screening for cytotoxicity 
(on HepG2 cells) and hemocompatibility (hemolysis assay) 
showed good safety of the new compounds, where ethyl 
5-(4-bromophenyl)-1-(1-(2-(4-hydroxy-3-methoxybenzylidene)-
hydrazineyl)-1-oxo-3-phenylpropan-2-yl)-2-methyl-1H-pyr-
role-3-carboxylate (4d) and ethyl 5-(4-bromophenyl)-1-(1-(2-(2-
hydroxybenzylidene)hydrazineyl)-1-oxo-3-phenylpropan- 
-2-yl)-2-methyl-1H-pyrrole-3-carboxylate (4a) were the least 
toxic. The antioxidant activity in terms of radical scavenging 
activity (DPPH test) and reducing ability (ABTS) was also evalu-
ated. The antioxidant protective potential of the compounds 
was next determined in different in vitro cellular-based models, 
revealing compounds 4d and 3 [ethyl 5-(4-bromophenyl)-1-(1- 
-hydrazineyl-1-oxo-3-phenylpropan-2-yl)-2-methyl-1H-pyrrole- 
-3-carboxylate] as the most promising compounds, with 4d 
having better safety profile.
Keywords: pyrrole hydrazones, DPPH, ABTS, cytotoxicity, micro-
somes, oxidative stress
Pyrroles and their derivatives represent one of the most important groups of N-hetero-
cyclic compounds because of their remarkable antibacterial, antiviral, anti-inflammatory, 
antitumor, and antioxidant activities (1). Recent studies of different benzoxazolyl, benzo-
thiazolyl, benzimidazolyl-pyrroles with amide structure have been reported, displaying 
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Hydrazones represent a special group of compounds in the Schiff ś base family. They 
are usually synthesized via condensation of primary amines with active carbonyl groups; 
they represent active pharmacophores and fragments for the development of new drugs 
(3). Hydrazone derivatives possess a wide variety of biological activities such as anticancer 
(4–7), antioxidant (8, 9), antimycobacterial (10, 11), anti-inflammatory (12), antidepressant 
(13), antihypertensive (14), antimicrobial (15, 16) and anticonvulsant activity (17, 18).
Despite scientists’ efforts to increase the number of compounds in chemolibraries to 
obtain better results on the search for hits, most of the compounds are often discarded in 
clinical phase II due to pharmacokinetic problems. Thus, the current research approach is 
focused on finding the key points in a compound’s pharmacokinetic and pharmacodynamic 
properties that can be set as standards for drug design. These processes are, sometimes, 
referred to as drug-likeness or drug-like molecules recognition (19) and are used as a start-up 
point in drug design of pharmacologically active molecules.
Many aspects of drug-like properties can be quantified through physicochemical 
indices and these, in turn, can be calculated in silico. Criteria such as the Lipinski’s rule of 
five (20) can be used to filter libraries and remove molecules with predicted poor drug-like 
properties that serve only to waste valuable drug development resources (21). Physico-
chemical features, like hydrophobicity, electronic distribution, hydrogen bonding 
characteristics, molecule size and flexibility, are often applied as pharmacophoric proper-
ties indicating the similarity of a newly synthesized molecule to the known drugs. This 
similarity is often called drug-likeness and is a good predictive tool for the preliminary 
evaluation of the behavior of a new molecule in a living organism in regard to bioavailability, 
transport properties, affinity to proteins, reactivity, toxicity, metabolic stability and many 
others (20).
Oxidative stress represents the impaired balance between reactive oxygen species 
(ROS) formation and the capacity to overcome ROS-induced danger in the body. It plays a 
significant role in the pathogenesis and pathophysiology of different diseases, including 
cardiovascular, neurodegenerative, oncological, inflammatory, etc. (22, 23). Thus, the role 
of antioxidants in the prevention and treatment of oxidative stress-related conditions is 
continuously increasing and many efforts have been targeted on the synthesis of new anti-
oxidants with low cytotoxicity (24–26). Among them, different compounds containing a 
pyrrole moiety have been reported to possess antioxidant activity (27, 28).
Different hydrazones have also been reported to exert antioxidant properties by free-
radical scavenging mechanisms (29). Most probably, an azomethine group in the structure 
of hydrazones contributes to their potent antioxidant activity (30). 
Beside their favorable pharmacological effects, many new drug candidates fail to 
complete the drug development process due to different safety concerns. Therefore, the 
preliminary assessment of potential toxicity is an important step in early safety evaluation 
of newly developed compounds. It is substantially easier to utilize cell-based in vitro models 
to examine sub-cellular events, compared to higher levels of biological organization, i.e., 
whole organisms. Different in vitro models comprising subcellular fractions (i.e., liver 
microsomes), transformed cell lines (i.e., immortalized human hepatocytes cell HepG2 
cells) or primary cells (i.e., isolated blood cells) provide additional information and are a 
useful tool in preliminary safety assessment (31).
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In this study, we aimed to combine the two active principles of pyrrole moiety and 
hydrazine pharmacophore in a series of pyrrolylhydrazide-hydrazones (3, 4a-g) with po-
tential antioxidant activity. The pharmacokinetic behavior of the new structures was pre-
dicted through the calculation of molecular descriptors defined in the “Lipinski’s rule of 
five” as an appropriate tool to distinguish drug-like from non-drug-like substances. In 
addition, in vitro toxicity evaluation on HepG2 cells and hemolysis study were carried out 
as a part of the initial safety screening for hemocompatibility and cytotoxicity of the newly 
synthesized hydrazones. The antioxidant activity was evaluated using ABTS and DPPH 
tests for radical scavengers’ activity. Different in vitro cellular-based models of H2O2- 
- induced oxidative damage and Fe2+/ascorbic acid-induced lipid peroxidation were applied 
for evaluation of the antioxidant protective potential of the compounds.
EXPERIMENTAL
Materials and methods
The final hydrazones were synthesized in a micro-scale synthesis apparatus (Aldrich 
Micro-LabKit, USA) assuring low harmful emissions and reagent economy. The melting 
points were measured in a capillary digital melting point apparatus IA 9200 (Electrothermal, 
UK) and were not corrected. The synthesis progress was controlled by TLC on aluminium 
sheets Silicagel 60 F254 (Merck, Germany), using CHCl3/ethanol (10:1) as a mobile phase.
The IR spectra within 400–4000 cm–1 range were recorded on a Nicolet iS10 FT-IR spec-
trometer using ATR technique with Smart iTR adapter (Thermo Fisher Scientific, USA). 1H 
and 13C NMR spectra were registered on Bruker Spectrospin WM600 spectrometer (Bruker, 
Switzerland) at 600 MHz, as d (ppm) relative to TMS as internal standard, and the coupling 
constants (J) are expressed in hertz (Hz). All NH protons were D2O exchangeable. The re-
lated mass spectra were obtained from a 6410 Agilent LCMS triple quadrupole mass 
spectrometer (LCMS) with an electrospray ionization (ESI) interface (Agilent Technologies, 
USA). Elemental analyses were performed on Euro EA 3000-Single analyser (EuroVector 
S.p.A, Italy). All chemical names were generated by using the structure-to-name algorithm 
of ChemBioDraw Ultra software, Version 12.0, CambridgeSoft, PerkinElmer Company, USA. 
All commercial chemicals and reagents used as starting materials in this study were 
research-grade chemicals, purchased from Merck. The molecular descriptors were deter-
mined using the free web-based server Molinspiration Cheminformatics (Molinspiration 
Cheminformatics, Bratislava University, Slovak Republic) (32, 33). Human hepatoma cells 
HepG2 were purchased from ATCC (Manassas, VA, USA). HepG2 cells were grown according 
to the standard protocol. The cells were cultured in DMEM cell medium (4500 mg L–1 glucose, 
without L-glutamine) with 10 % fetal bovine serum, 2 mmol L–1 L-glutamine, 1 % penicillin/1 
% streptomycin 100× at 37 °C in an atmosphere of 5 % CO2 in a humidified incubator.
Animals
Male Wister rats (200–220 g) were provided by National Breeding Centre, Sofia, 
Bulgaria). They were housed under standard conditions of temperature (20 ± 5 °C), fed 
with standard pellet diet and free access to water. The experimental procedures were 
approved by the Institutional Animal Care and Use Committee at the Medical University, 
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Sofia, Bulgaria. The principles stated in the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123) and 
Principles of Laboratory Animal Care (NIH publication #85–23, revised in 1985) were 
followed strictly throughout the experiment.
Syntheses
2-(5-(4-Bromophenyl)-3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl)-3-phenyl-propanoic acid 
(1). – It was synthesized applying the classical Paal-Knorr cyclization procedure, as already 
explained (34). In the current synthesis, L-phenylalanine was used as a primary amine and 
ethyl 2-acetyl-4-(4-bromophenyl)-4-oxobutanoate was used as a β-dicarbonyl compound. 
The intermediate dicarbonyl molecule was prepared by C-alkylation of commercially 
available 2-bromo-1-(4-bromophenyl)ethanone with ethyl 3-oxobutanoate and the final 
β-dicarbonyl compound was used in situ.
Ethyl 5-(4-bromophenyl)-1-(1-ethoxy-1-oxo-3-phenylpropan-2-yl)-2-methyl-1H-pyrrole-3-
carboxylate (2). – SOCl2 (0.04 mol) was added dropwise at 0 °C, under intensive stirring, to 
50 mL dry ethanol, used as a solvent. Thereafter, 0.01 mol of compound 1 was added 
immediately and the mixture was refluxed for 2–3 h to complete the reaction (TLC 
control). The solvent was removed under reduced pressure and the resulting oil was 
dissolved in chloroform and washed successively with 5 % solution of Na2CO3 and water. 
The organic layer was dried over Na2SO4 and evaporated under reduced pressure (34). 
The obtained compound 2 was used in the next step without isolation and additional 
purification.
Ethyl 5-(4-bromophenyl)-1-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)-2-methyl-1H-pyrrole- 
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of the obtained ethyl ester 2, according to the general procedure given in Scheme 1, as 
follows: 0.01 mol of the ethyl ester (2) and 0.02 mol hydrazine hydrate (100 %) were dissolved 
in 15 mL ethanol (99.7 %). The mixture was refluxed for 4 h to complete the hydrazinolysis 
of the remote ester group (TLC control). The product was isolated after cooling as a white 
solid and was recrystallized from ethanol.
General procedure for the synthesis of the targeted hydrazones (4a-f). – Equimolar quantities 
of carbohydrazide 3 and 1.8 mmol of either of the carbonyl partners 2-hydroxybenzalde-
hyde (a), 4-(dimethylamino)benzaldehyde (b), 4-methoxybenzaldehyde (c), 4-hydroxy-
3-methoxybenzaldehyde (d), furan-2-carbaldehyde (e) or indoline-2,3-dione (f) (Fig. 1) were 
dissolved in 1.5 mL glacial acetic acid in a reaction vial of 5 mL and stirred at 100 °C for 
40–50 min to complete the reaction (under TLC control) (Scheme 2). The products were 
isolated after adding water and recrystallized from ethanol.
Physico-chemical and spectral data are given in Tables I and II.
Drug-likeness estimation
The molecular descriptors and drug-likeness estimation of the target compounds 
were based on parameters calculated through Molinspiration Cheminformatics free based 
web server using the incorporated molecular processing and property calculation toolkits 
(32, 33).
Pharmacological evaluations
Cytotoxicity determination (MTT-dye reduction assay). – HepG2 cells were seeded in 96- 
-well microplates at a density 2 × 104 cells per well, allowed to attach to the well surface for 
24 h at 37 °C in a humidified atmosphere with 5 % CO2. After incubation, different 
concentrations (1.0, 5.0, 10.0, 50.0, 75.0, 100.0, 250.0, 500.0 μmol L–1) of the synthesized 
Fig. 1. Structures of the used carbonyl partners: 2-hydroxybenzaldehyde (a), 4-(dimethylamino)benz-
aldehyde (b), 4-methoxybenzaldehyde (c), 4-hydroxy-3-methoxybenzaldehyde (d), furan-2-carbalde-
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 N-pyrrolylhydrazide hydrazones in DMSO were added to the cells and incubated for a 
period of 24 h (the final concentration of DMSO was below 0.5 %). At least 8 wells were 
used for each concentration. After the treatment, the culture medium was replaced by 
medium containing MTT solution and the cells were incubated for 3 h at 37 °C. Intracel-
lularly formed formazan crystals were dissolved by the addition of 100 μL DMSO per well 
and absorbance was measured in a multiplate reader Synergy 2 (BioTek Instruments, USA) 
at 570 nm (690 nm for background absorbance).
In the oxidative stress model, cells (5 × 104 cells per well) were exposed to 0.1 mmol L–1 
H2O2 for 1 h to obtain submaximal cytotoxicity (approximately 40 % vs. untreated controls). 
In order to estimate protection, cells were pre-treated for 1 h with the tested compounds 3, 
4a-f (1–20 μmol L–1) before the H2O2 pulse. Viability was assayed after 24 h by MTT-dye 
reduction assay. Data are normalized and are expressed as a percent of protection vs. H2O2 
treatment (set as 0 %.)
Red blood cell hemolysis assay. – The hemolytic potential of the test substances was 
evaluated according to a protocol described by Evans et al. (35). Healthy volunteers‘ blood 
specimens were obtained from a certified clinical laboratory. The experimental procedures 
were approved by the Institutional Ethical Committee (KENIMUS) at the Medical 
University, Sofia, Bulgaria and conducted according to corresponding protocols. The 
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and were subsequently resuspended in phosphate buffer, pH 7.4. Test substances (25.0, 50.0 
and 100.0 μmol L–1 in DMSO, final DMSO concentration < 0.1 %), positive (Triton X-100, 0.2 
%) and negative (distilled water) controls were pipetted to 96-well plates and then 
erythrocyte suspension in phosphate buffer was added to each well. After incubation for 
1 h at 37 °C, the plates were centrifuged at 500×g and the supernatant was transferred to 
new 96-well plates, and the absorbance of hemoglobin was measured at 430 nm in a 
Synergy 2 plate reader (BioTek Instruments). The results were represented as a percentage 
over positive controls’ hemoglobin absorbance values, with the negative controls’ values 
being accepted as zero hemolysis.
Radical scavenging activity determination. – 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radi-
cal scavenging activity assay was performed to assess the antioxidant properties of com-
pounds 3 and 4a-f according to the method reported by Brand-Williams et al. (36). The 
samples were mixed with 0.56 mmol L–1 DPPH solution. The mixture was kept in dark for 
30 min at 25 °C, after that the decrease in absorbance was measured at 517 nm. Trolox was 
used as a reference. All determinations were performed in triplicate.
In ABTS•+ assay the antioxidant activity of the obtained compounds 3, 4a-f was mea-
sured using a modification for 96-well plates in the method of Re et al. (37). The ABTS•+ 
radical solution was prepared by mixing ABTS (9.5 mL, 7 mmol L–1) with potassium per-
sulfate (245 μL, 100 mmol L–1), reaching the final volume of 10 mL with distilled water. The 
solution was kept in dark for 18 h (at room temperature), and then diluted with potassium 
phosphate buffer (0.1 mol L–1, pH 7.4) to an absorbance of 0.70 (± 0.02) at 734 nm. The sam-
ples were prepared in ethanol. The samples (50 μL) were placed in 96-well microplates and 
mixed thoroughly with 50 μL ABTS•+ radical working solution. Absorbance was measured 
at 734 nm. All determinations were performed in triplicate.
Isolation of rat liver microsomes and iron-ascorbic acid-induced lipid peroxidation assay (LPO). 
– The animals were fasted overnight and were sacrificed by cervical decapitation. Livers 
were thoroughly perfused with 1.15 % KCl and homogenized with four volumes of ice-cold 
0.1 potassium phosphate buffer, pH = 7.4. The liver homogenate was centrifuged at 9 000×g 
for 30 min at 4 °C and the resulting postmitochondrial fraction (S9) was centrifuged at 
105,000×g for 60 min at 4 °C. The microsomal pellets were re-suspended in 0.1 mol L–1 
potassium phosphate buffer, pH = 7.4, containing 20 % glycerol. Microsomal protein 
content was determined according to Lowry et al. (38).
The microsomes were preincubated with compounds 3 and 4a-f (20 μmol L–1) at 37 °C 
for 30 min. The LPO was started with a solution of iron sulphate 20 μmol L–1 and ascorbic 
acid 0.5 mmol L–1 (39). The reaction was stopped after 20 min by adding a mixture of TCA 
25 % and thiobarbituric acid (TBA) 0.67 %, and malondialdehyde (MDA) content was de-
termined (40). The absorbance was measured at λ = 535 nm (Spectro UV-VIS Split 
spectrophotometer, Jenway, UK). The amount of MDA was calculated using a molar 
extinction coefficient of 1.56 × 105 L mol–1 cm–1. The final results were presented as a per-
centage of only Fe2+/AA-treated positive control (set as 100 %).
Statistical analysis
Statistically significant differences between IC50 values of each couple of compounds 
were detected based on the 95 % confidence intervals. The IC50 values and their respective 
confidence intervals were calculated by means of GraphPad Prism Software.
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In some experiments, statistical analysis was performed by one-way ANOVA, fol-
lowed by a Bonferroni test for multiple comparisons. Statistical evaluation was performed 
using the GraphPad Prism 5.0 software. Results are expressed as a mean ± SD (n = 3). Values 
of p < 0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Syntheses and chemical characterization
The initial N-pyrrolylcarbohydrazide (3) was obtained through a multistage process, 
based on the classical Paal-Knorr cyclization for the synthesis of the initial N-pyrrolyl-
carboxylic acid (1), its esterification and as a final stage, selective hydrazinolysis of the 
obtained diester (2), as presented in Scheme 1. We observed that, while the hydrazinolysis 
of pyrrolecarboxylic esters was known to succeed at relatively severe conditions, 
hydrazinolysis of those non-conjugated with the pyrrole ring ester groups was found to be 
completed in a few hours in ethanol, due to the higher carbonyl activity (34). On the basis 
of this peculiarity, a selective hydrazinolysis was achieved with mixed-type diesters, 
which made possible the preservation of the ester groups in position-3 as a prerequisite for 
receptor binding (11, 34).
The general synthesis of the target hydrazones 4a-f was carried out according to the 
procedures defined in Scheme 2, through condensation of the corresponding N-pyrrolyl-
hydrazide (3) with any of the carbonyl compounds: 2-hydroxybenzaldehyde (a), 4-(dimethyl-
amino)benzaldehyde (b), 4-methoxybenzaldehyde (c), 4-hydroxy-3-methoxybenzaldehyde 
(d) and furan-2-carbaldehyde (e) or indoline-2,3-dione (f) (Fig. 1).
The final hydrazones were synthesized in a micro synthesis apparatus, assuring 
about 62–93 % yields, low harmful emissions and reagent economy thus following the 
requirements of the green chemistry. The chemical names, melting points, yields and 
elemental analysis data for the obtained substances are presented in Table I.
The structures of the new compounds were elucidated with IR, 1H and 13C NMR 
spectral data and their purity was confirmed through elemental analysis. The spectral 
results corresponded with the assigned structures and are presented in Table II.
The IR spectra of the synthesized hydrazones 4a-f revealed the presence of character-
istic signals for two sets of amide I and amide II between 1680–1697 cm–1 and 1559–1571 
cm–1, resp. The observed bands in the range of 1709–1739 cm–1 pointed to the presence of 
the ester group at 3rd position in the pyrrole ring. The signals appearing between 3192 and 
3226 cm–1 are characteristic for the presence of the hydrazide-hydrazone group.
In the obtained 1H NMR spectra the NH signals for the CONH-N group were visible 
as a sharp singlet between 7.26 and 7.29 ppm. The characteristic signal for the C4 proton in 
the pyrrole ring is appearing as a singlet in the range of 6.37 to 6.50 ppm. In the spectral 
data are observed changes in the signals from the СН=N proton (a signal is missing in 
spectrum of 4f), whereas the corresponding CH=N signals from the hydrazone group for 
all other derivatives are observed in the range from 7.81 to 10.70 ppm. The presence of the 
furan ring in the structure of 4e shifts this signal to 7.72 ppm. Characteristic for the spectra 
are the triplet at 5.89 ppm and the doublet at 3.38 ppm for the phenyl fragment in the struc-
ture. In the obtained 13C NMR spectra most characteristic is the signal for the CH=N group, 
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which is observed at 142.5 ppm for the substituted benzaldehyde fragments, while for the 
furan (4e) and isatin (4f) containing derivatives this signal is shifted to 152.9 and 134.8 ppm, 
resp. All NH and OH signals were D2O exchangeable.
The chemical structures of the new compounds were supported by MS spectral data. 
Molecular ion peaks corresponding to the expected molecular masses were obtained for 
all compounds. The m/z values and the expected relative molecular masses are given in 
Table II, while the corresponding 1H NMR and mass spectra are available as Supplemen-
tary Material.
Drug-likeness estimation with “Lipinski’s rule of five”
The “Lipinski’s rule of five” was applied for assessment of the reliability of the syn-
thesized new N-pyrrolylhydrazide-hydrazones as possible prototypes for small molecules 
with favorable cell membrane permeability [including blood-brain barrier (BBB) permea-
bility] and improved bioavailability. 
According to the “Lipinski‘s rule of five”, there are five key physicochemical 
parameters: molecular mass, lipophilicity, polar surface area, hydrogen bonding and 
charge, which have a significant impact on drug’s BBB permeability, especially via passive 
diffusion. Poor BBB permeation is more likely to occur when there are more than 5 H-bond 
donors and 10 H-bond acceptors and when Mr is greater than 500 and calculated logP 
(ClogP) is greater than 5 (20). The effect of these physicochemical parameters on the 
interaction between the drug molecule and the lipophilic cell membrane is essential for the 
good pharmacokinetic behavior and lack of metabolism concerns for the new molecules 
designed as pharmacologically active substances (41).
The required Lipinski’s parameters were calculated using the Molinspiration 
cheminformatics web server and the obtained results are presented in Table III.




logP Mr HBA HBD TPSA
3 3.21 470.37 6 3 86.36 79.20
4a 6.57 574.48 7 2 92.93 76.93
4b 6.73 601.54 7 1 75.94 82.80
4c 6.68 588.50 7 1 81.94 80.73
4d 5.96 604.50 8 2 102.16 73.75
4e 5.88 548.44 7 1 85.84 79.38
4f 5.86 599.49 8 2 105.56 72.58
HBA – number of hydrogen bond acceptors, HBD – number of hydrogen bond donors,  
TPSA – topological polar surface area
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In addition, as a tool for oral absorption evaluation, the corresponding percentage 
absorption (%ABS) was also calculated for the target compounds, using the proposed 
formula (42):
 %ABS = 109 – 0.345 × TPSA
where TPSA stands for topological polar surface area.
The obtained values for logP demonstrated that the target molecules possess 
hydrophobic properties which would facilitate their transport through the cell membranes 
and would contribute to a good absorption. The theoretical values for %ABS additionally 
confirm this observation. Except for the initial N-pyrrolylcarbohydrazide (3), all the target 
hydrazones violate the “Lipinski’s rule of five” limitations for two parameters, logP and 
Mr with hydrophobic parameter logP being greater than 5 and molecular mass greater 
than 500, which should be considered and, if possible, avoided in future optimizations and 
design of other analogs.
Pharmacological evaluations
In vitro cytotoxicity evaluation on HepG2 cells. – The hepatotoxicity is one of the major 
causes of drug candidate withdrawals from the clinical studies and from the market (43, 
44).
In order to check the safety profile of the newly synthesized compounds, we have 
evaluated their effect on the viability of HepG2 cells through the MTT (tetrazolium dye, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. HepG2 cells have 
proven to be an appropriate system for the preliminary evaluation of cytotoxicity for 
several chemical compounds (45, 46) including selected N-substituted pyrrolyl hydrazones, 
as they maintain many of the specialized functions of normal human hepatocytes (47, 48).
The calculated IC50 values of compounds 3 and 4a-f are listed in Table IV. In general, 
all compounds (3, 4a-f) did not show significant cytotoxicity against HepG2 cells. The cor-
responding IC50 values were in the range of 52.99–82.29 μmol L–1. It should be noted that 
compounds 4a and 4d, with estimated IC50 values of 82.29 and 70.11 μmol L–1, resp., were 
the least toxic, therefore, most perspective from a safety point of view, followed by 4f, 4b, 
4e, 3 and 4c. 
Hemolysis assay. – In vitro assessment of the hemolytic potential of the newly synthe-
sized compounds is essential part of their toxicity evaluation. Therefore, we applied hemo-
lysis test assay in vitro to determine the eventual interaction of the newly synthesized 
 N-pyrrolylhydrazide hydrazones with blood components as a necessary part of their 
 biocompatibility in early preclinical development. The effects of the test substances 3, 4a-f 
in isolated human erythrocytes were assayed as a function of a compound’s concentration 
(25.0, 50.0 and 100.0 μmol L–1) in erythrocyte suspensions as described in Experimental 
section. The hemolytic activity of the tested compounds was compared to the effects of 
Triton X 100 (0.2 %) in the same erythrocyte samples, as shown in Fig. 2. Triton induces 
complete hemolysis after 1 h of incubation (100 %). In contrast, all tested newly synthesized 
derivatives did not promote any hemolytic effects. In particular, we found that the hemoly-
sis rate of the compounds 3 and 4a-f at concentrations of up to 50 μmol L–1 was lower than 
5 % and this result was up to the standard according to ISO/TR7405-1984(E). A slight 
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Table IV. IC50 values for in vitro cytotoxicity evaluation of the target compounds 








a IC50 values for in vitro cytotoxicity evaluation of the target compounds as a robust parameter, appropriate for the 
comparison of overall cytotoxicity in a mechanism-independent manner.
Fig. 2. Hemolytic effects of: a) compound 3 and b-g) compounds 4a-f on human erythrocytes. The 
results are expressed as a mean ± SD of three independent experiments. Significant difference vs. 
control: *p < 0.001; vs. Triton X-100: #p < 0.001.
a)                                                    b)                                                  c)
d)                                                    e)                                                  f)
g)
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 increase in hemolytic potential of 3, 4c and 4e was observed at the concentration 100 μmol L–1, 
but this concentration is quite high and unlikely to be used in vivo. Our results confirmed 
a good hemocompatibility of the tested hydrazones, indicating their appropriateness as 
potential pharmacophores. The safest and the most promising compounds were 4d and 4a, 
showing no hemolytic potential even at the highest tested concentration of 100 μmol L–1.
DPPH assay. – The scavenging activity in DPPH (1,1-diphenyl-2-picrylhydrazyl) assay 
is attributed to the hydrogen donating ability of antioxidants. The antioxidant effects of 
compounds 3 and 4a-f (31–250 μmol L–1) were studied. The results are compared with 
those of Trolox at same concentrations and are presented in Fig. 3. At the applied concen-
trations Trolox is an effective scavenger of DPPH radical, in contrast to melatonin. Com-
pounds 3 and 4d scavenge DPPH radical in a concentration-dependent manner like Trolox, 
but less effectively than Trolox (Fig. 3).
The mechanism of antioxidant activity of compounds 4d and 3 is most probably due 
to the reducing capacity, related to their chemical structure as pyrrole-based hydrazide-
hydrazones. In fact, a recent study by Khan et al. (29) showed that 2,4,6-trichlorophenylhy-
Fig. 3. Antioxidant capacity of compounds 3, 4a-f, applied at concentrations 31 to 250 μmol L–1, deter-
mined by: a) DPPH and b) ABTS*+ radical scavenging assays. Mean values of negative solvent controls 
(C) and experimental data ± standard deviation (SD) (n = 3). Significant difference vs. negative control: 
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drazine Schiff bases exhibited significant scavenging ability against DPPH radicals, the 
effect being attributed to their chemical structure. Sıcak et al. (49) also reported good anti-
oxidant activity of novel fluorine-containing chiral hydrazide-hydrazones by means of 
their radical scavenging activity determined by ABTS and DPPH assays.
ABTS•+radical decolorization assay. – In the applied concentrations (31–250 μmol L–1), both 
Trolox and melatonin were effective antioxidants with melatonin being more effective at 31 
μmol L–1 and Trolox at 250 μmol L–1. Among the tested compounds, compound 3 is the most 
effective scavenger of ABTS•+ radical, being more effective than melatonin and Trolox. Com-
pound 4d showed favorable antioxidant activity at 250 μmol L–1 comparable to melatonin. 
Compound 4a exerts a relatively week ABTS•+ radical scavenging activity while compounds 
4b, 4c, 4e and 4f did not scavenge ABTS•+ radical at the applied concentrations (Fig. 3).
Fe2+/AA-induced lipid peroxidation. – In vitro antioxidant properties of compounds 3, 4a-f 
were investigated in iron/ascorbic acid (Fe2+/AA) induced lipid peroxidation in isolated rat 
liver microsomes (Fig. 4). This model system is commonly used for induction of non-enzy-
matic lipid peroxidation. None of the tested compounds (3, 4a-f) induced lipid peroxidation 
in isolated rat liver microsomes as measured through malondialdehyde content, thus sug-
gesting that they had no pro-oxidant activity itself (results not shown). In contrast, Fe2+/AA 
treatment caused a significant (three-fold) increase in the amount of MDA vs.  untreated 
controls. It was observed that Fe2+/AA-induced lipid peroxidation was significantly attenu-
ated in isolated rat liver microsomes by compounds 4d and 3, as measured by a decrease in 
MDA levels (p < 0.001). Melatonin (N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-acetamide) was 
used as a reference substance, because of its well-known antioxidant and free radical 
 scavenger properties (50–52). Melatonin decreased MDA levels by 37 % (p < 0.001). The pro-
tective effects of 4d and 3 on lipid peroxidation were even higher than those of melatonin; 
they decreased MDA content by 82 and 58 %, resp. (p < 0.001) (Fig. 4). Compound 4f dimin-
Fig. 4. Protective effects of compounds 3 and 4a-f (20 μmol L–1) on the levels of MDA in a model of 
Fe2+/AA-induced lipid peroxidation in isolated rat liver microsomes. Data are normalized and 
presented as percentage of the Fe2+/AA treated group (set as 100 %). Mean ± SD (n = 3). Significant 
difference vs. control (untreated microsomes): *p < 0.001; vs. melatonin: ++p < 0.01, +++p < 0.001.
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ished the levels of MDA by 35 %, while the protective effects of compounds 4a, 4b, 4c and 4e 
were less pronounced, showing a decrease in MDA levels by 21, 22, 22 and 24 %, resp. 
H2O2-induced oxidative stress in HepG2 cells. – Potential protective effects of compounds 
3 and 4a-f against oxidative stress induced by H2O2 in HepG2 cells were also investigated 
(Fig. 5). For this evaluation, we had selected the human hepatoma HepG2 cells as a well-
Fig. 5. Protective effects of the compounds 3 and 4a-f on cell viability in H2O2-induced oxidative stress 
in HepG2 cells in vitro. Data are expressed as % protection; mean ± SD (n = 6). Significant difference 
vs. H2O2-treated controls: *p < 0.05, **p < 0.01, ***p < 0.001; vs. melatonin at respective concentration: 
#p < 0.05, ##p < 0.01, ###p < 0.001.
a)                                                            b)
c)                                                            d)
e)                                                            f)
g)                                                            h)
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controlled, biological model system, characterized by stable phenotype, unlimited life 
span, high availability, expression of xenobiotic transcription factors, phase I and II drug 
metabolism enzymes and transporters (47). HepG2 cell line is an appropriate tool for 
studying the cytoprotective effects of different natural and synthetic compounds (53).
The cells were pre-treated with tested compounds at a concentration of 0.1, 1, 10 and 
20 μmol L–1, and then were exposed them to H2O2, as described in Experimental section. 
Cell mitochondrial function, measured by MTT-assay, was used as a marker to evaluate 
the effects on cell viability. The treatment with 0.1 mmol L–1 H2O2 (1 h) caused a significant 
decrease in cell viability by 42 % vs. untreated control cells (p < 0.01, results not shown). 
Pretreatment for 1 h of HepG2 cells with compound 4d (0.1, 1, 10 and 20 μmol L–1) signifi-
cantly increased the cell survival by 35, 45, 69 and 81 %, resp., vs. H2O2 treatment (Fig. 5e). 
The antioxidant protection was even higher than that of the reference compound melato-
nin, which at the same concentrations increased the cell survival by 36, 52, 57 and 68 %, 
resp. (Fig. 5h). Significantly higher increase in survival compared to melatonin at 10 μmol 
L–1 was observed for 4a, 4c, 4d and 4f (Figs. 5b,d,e,g,h). Compounds 3 and 4e were also 
effective, showing comparable effects to melatonin (Figs. 5a,f,h), whereas 4a, 4b, 4c and 4f 
showed lower antioxidant protection (Figs. 5b,c,d,g).
CONCLUSIONS
One new N-pyrrolylcarbohydrazide (3) and six new N-pyrrole hydrazones (4a-f) were 
synthesized. Except for the initial N-pyrrolylcarbohydrazide, all target hydrazones violate 
the “Lipinski’s rule of five” limitations on two parameters, logP and Mr. On the other hand, 
all compounds possess hydrophobic properties which would facilitate their passing 
through the cell membranes and would contribute to a good absorption. This conclusion 
is further confirmed by the high values of %ABS. The in vitro safety screening tests for 
cytotoxicity on HepG2 cells and hemocompatibility (hemolysis assay) showed good safety 
profile of the new compounds with 4d and 4a defined as the least toxic. The in vitro anti-
oxidant activities of the newly-synthesized compounds 3 and 4a-f was assessed by DPPH 
and ABTS*+ tests and showed that compound 3 was the most potent radical scavenger, 
followed by 4d in ABTS•+ radical discoloration assay, whereas 4d was slightly better in 
DPPH assay. Further, our in vitro protection study proved efficient prevention against 
oxidative stress in H2O2-induced injury in HepG2 cells, especially by compounds 4d and 
3. Both compounds (4d and 3) were also the most effective protectors in the model of Fe2+/
AA-induced lipid peroxidation, showing a significant attenuation of peroxidation in iso-
lated rat liver microsomes. This study revealed that the most promising compounds with 
potent antioxidant activity were 4d and 3. Nevertheless, 4d possesses a better safety profile 
than all other evaluated newly-synthesized compounds and was proven as the most per-
spective for further investigations of pharmacological properties.
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